deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00535574

Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia

Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia: a 6-week, Randomized, Double-blind Placebo-controlled Trial

Sponsor: Beersheva Mental Health Center

Conditions Schizophrenia
Interventions Bexarotene (Targretin LGD1069) bexarotene
Updated 6 times since 2017 Last updated: Jul 25, 2012 Started: Nov 30, 2008 Primary completion: Dec 31, 2010 Completion: May 31, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00535574, this PHASE3 trial focuses on Schizophrenia and remains completed. Sponsored by Beersheva Mental Health Center, it has been updated 6 times since 2008, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beersheva Mental Health Center
Data source: Beersheva Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations